Public Release: 

Study compares outcomes for different methods of drug-releasing stent implantation

The JAMA Network Journals

Myeong-Ki Hong, M.D., Ph.D., of the Yonsei University College of Medicine, Seoul, Korea and colleagues randomly assigned 1,400 patients with long coronary lesions to receive intravascular ultrasound-guided (n = 700) or angiography-guided (n = 700) everolimus-eluting stent implantation. This JAMA study is being released to coincide with its presentation at the American Heart Association's Scientific Sessions 2015.

Even though recent guidelines recommend the use of intravascular ultrasound (IVUS) to optimize stent implantation for select patients, the effect of IVUS-guided drug-eluting (releasing) stent implantation on clinical outcomes remains uncertain because of the limited number of properly powered randomized trials.

For this trial, one-year follow-up was complete in 1,323 patients (94.5 percent). Major adverse cardiac events (including cardiac death, target lesion-related heart attack, or ischemia-driven target lesion revascularization) at 1 year occurred in 39 patients (5.8 percent) undergoing angiography-guided and in 19 patients (2.9 percent) undergoing IVUS-guided stent implantation (a 2.9 percent absolute reduction and 48 percent relative reduction). The difference was driven by a lower risk of ischemia-driven target lesion revascularization in patients undergoing IVUS-guided (17 [2.5 percent]) compared with angiography-guided (33 [5 percent]) stent implantation.

Cardiac death and target lesion-related heart attack were not significantly different between the 2 groups. For cardiac death, there were 3 patients (0.4 percent) in the IVUS-guided group and 5 patients (0.7 percent) in the angiography-guided group. Target lesion-related heart attack occurred in 1 patient in the angiography-guided stent implantation group.

"Our findings suggest better clinical outcomes for major adverse cardiac events with IVUS-guided stent implantation compared with angiography-guided stent implantation, particularly for diffuse long lesions," the authors write.


(doi:10.1001/jama.2015.15454; Available pre-embargo to the media at

Editor's Note: This study was supported by the Cardiovascular Research Center (Seoul, Korea) and funded by Abbott Vascular Inc. The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.